- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00162123
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
2016년 6월 28일 업데이트: Bristol-Myers Squibb
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
The purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment.
In addition, this study will continue to follow patients who have taken ipilimumab, but who are not eligible for maintenance or reinduction therapy.
연구 개요
연구 유형
중재적
등록 (실제)
248
단계
- 2 단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
Gauteng
-
Johannesburg, Gauteng, 남아프리카, 2199
- Local Institution
-
-
Western Cape
-
Cape Town, Western Cape, 남아프리카, 7570
- Local Institution
-
-
-
-
-
Oslo, 노르웨이, 0310
- Local Institution
-
-
-
-
-
Aarhus C, 덴마크, 8000
- Local Institution
-
-
-
-
-
Berlin, 독일, D-12200
- Local Institution
-
Heidelberg, 독일, 69120
- Local Institution
-
Kiel, 독일, D-24105
- Local Institution
-
-
-
-
-
St. Petersburg, 러시아 연방, 191104
- Local Institution
-
Stavropol, 러시아 연방, 355047
- Local Institution
-
Voronezh, 러시아 연방, 394000
- Local Institution
-
-
-
-
Arizona
-
Tucson, Arizona, 미국, 85719
- University of Arizona Cancer Center
-
-
California
-
Laverne, California, 미국, 91750
- Wilshire Oncology Medical Group Inc
-
Los Angeles, California, 미국, 90033
- USC/Norris Comprehensive Cancer Center
-
Los Angeles, California, 미국, 90025
- The Angeles Clinic & Research Inst.
-
San Francisco, California, 미국, 94115
- San Francisco Oncology Associates
-
-
Connecticut
-
To come, Connecticut, 미국
- Local Institution
-
-
Florida
-
Jacksonville, Florida, 미국, 32207
- Baptist Cancer Institute
-
-
Illinois
-
Chicago, Illinois, 미국, 60637
- University of Chicago
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- Indiana Oncology Hematology Consultants
-
-
Missouri
-
Saint Louis, Missouri, 미국, 63110
- Washington University School of Medicine
-
St Joseph, Missouri, 미국, 64507
- St Joseph Oncology Inc
-
-
New York
-
New York, New York, 미국, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28203
- Carolinas Medical Center
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45219
- The Christ Hospital Cancer Center Research
-
-
Oregon
-
Portland, Oregon, 미국, 97213
- Providence Portland Medical Center
-
-
South Carolina
-
Greenville, South Carolina, 미국, 29615
- Cancer Centers of the Carolinas
-
-
Texas
-
Dallas, Texas, 미국, 75230
- Center For Oncology Research & Treatment, P.A.
-
Lubbock, Texas, 미국, 79410
- Joe Arrington Cancer Research and Treatment Center
-
-
Washington
-
Seattle, Washington, 미국, 98109
- University of Washington Medical Center
-
-
-
-
-
Brussels, 벨기에, 1090
- Local Institution
-
Brussels, 벨기에, 1070
- Local Institution
-
Bruxelles, 벨기에, 1200
- Local Institution
-
-
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, 브라질, 90610
- Local Institution
-
Porto Alegre, Rio Grande Do Sul, 브라질, 90050
- Local Institution
-
-
Sao Paulo
-
Jau, Sao Paulo, 브라질, 17210
- Local Institution
-
-
-
-
-
Malaga, 스페인, 29010
- Local Institution
-
Valencia, 스페인, 46009
- Local Institution
-
-
-
-
-
Buenos Aires, 아르헨티나, CP1280AEB
- Local Institution
-
-
-
-
-
Wels, 오스트리아, A-4600
- Local Institution
-
Wien, 오스트리아, 1090
- Local Institution
-
-
-
-
-
Dnepropetrovsk, 우크라이나, 49044
- Local Institution
-
-
-
-
-
Jerusalem, 이스라엘, 91120
- Local Institution
-
Tel-Aviv, 이스라엘, 64239
- Local Institution
-
-
-
-
-
Genova, 이탈리아, 16132
- Local Institution
-
Meldola (Fc), 이탈리아, 47014
- Local Institution
-
Rimini, 이탈리아, 47900
- Local Institution
-
Siena, 이탈리아, 53100
- Local Institution
-
-
-
-
-
Olomouc, 체코 공화국, 775 20
- Local Institution
-
-
-
-
Alberta
-
Calgary, Alberta, 캐나다, T2N 4N2
- Local Institution
-
Edmonton, Alberta, 캐나다, T6G 1Z2
- Local Institution
-
-
New Brunswick
-
Moncton, New Brunswick, 캐나다, E1C 6Z8
- Local Institution
-
-
-
-
-
Lodz, 폴란드, 90553
- Local Institution
-
Poznan, 폴란드, 61-866
- Local Institution
-
Wroclaw, 폴란드, 51-124
- Local Institution
-
-
-
-
-
Brest, 프랑스, 29200
- Local Institution
-
Lyon Cedex 08, 프랑스, 69373
- Local Institution
-
Paris, 프랑스, 75010
- Local Institution
-
Vandoeuvre Les Nancy, 프랑스, 54511
- Local Institution
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Key Inclusion Criteria
- Diagnosis of advanced melanoma
- Prior treatment in a prespecified prior/parent ipilimumab study
- Men and women 18 years of age and older
First Reinduction:
- No unacceptable toxicity (except select reversible immune-related adverse events) requiring ipilimumab discontinuation
- Had experienced documented progressive disease after expanded clinical benefit
Extended Maintenance
- Received ipilimumab at any dose in a parent study
- Achieved expanded clinical benefit at the time of entry to current study
Follow-up:
- Received ipilimumab at any dose in a closing parent study
- Deemed ineligible for reinduction or extended maintenance treatment or refused treatment as reinduction or extended maintenance at the time of screening in the current study, but consented to follow-up
Key Exclusion Criteria
- Prior treatment with a CD137 agonist or a cytotoxic T-lymphocyte antigen 4 inhibitor or agonist, other than ipilimumab
- Primary ocular or mucosal melanoma
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: First reinduction: Ipilimumab, 0.3 to 10 mg/kg
Participants who initially received ipilimumab, 0.3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study.
Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent.
Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
다른 이름들:
|
|
실험적: First reinduction: Ipilimumab, 3 to 10 mg/kg
Participants who initially received ipilimumab, 3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study.
Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent.
Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
다른 이름들:
|
|
실험적: First reinduction: Ipilimumab, 10 to 10 mg/kg
Participants who initially received ipilimumab, 10 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study.
Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent.
Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
다른 이름들:
|
|
실험적: Extended maintenance: Ipilimumab, 0.3 mg/kg
Participants who received ipilimumab, 0.3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (0.3 mg/kg) as maintenance in the current study.
Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
다른 이름들:
|
|
실험적: Extended maintenance: Ipilimumab, 3 mg/kg
Participants who received ipilimumab, 3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (3 mg/kg) as maintenance in the current study.
Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
다른 이름들:
|
|
실험적: Extended maintenance: Ipilimumab, 10 mg
Participants who received ipilimumab, 10 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (10 mg/kg) as maintenance in the current study.
Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
다른 이름들:
|
|
간섭 없음: Follow-up
Participants did not receive any additional study treatment in current study but continued follow-up for the collection of survival data.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants With On-study Adverse Events (AEs), AEs Leading to Discontinuation, Serious Adverse Events (SAEs), Drug-related AEs, Immune-related AEs (irAEs), and Death as Outcome
기간: Continuously from first dose to 70 days after last dose of study drug. For deaths, Day 1 of enrollment to 70 days after last dose of study drug.
|
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
An SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Drug-related is defined as having certain, probable, possible, or missing relationship to study drug.
An IrAE is an AE characterized by a potential association with inflammation and considered by the investigator to be drug related.
Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death.
|
Continuously from first dose to 70 days after last dose of study drug. For deaths, Day 1 of enrollment to 70 days after last dose of study drug.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Survival (OS)
기간: From first dose of study drug in parent study to death or date of last censoring.
|
OS was computed for all patients who entered this study and is defined as the time between the first dose of study therapy and death.
If a patient has not died, OS was censored at the time of last contact.
|
From first dose of study drug in parent study to death or date of last censoring.
|
|
Percentage of Participants Surviving at 1, 1.5, and 2 Years
기간: From first dose of study drug in parent study to up to 2 years after reinduction
|
Survival rate was defined as the time from first dose of study drug to 1, 1.5, and 2 years.
|
From first dose of study drug in parent study to up to 2 years after reinduction
|
|
Number of Participants With On-study Immune-related Adverse Events (irAEs)
기간: From first dose of study drug during reinduction to the earliest of 70 days after last dose or day before second reinduction first dose date
|
irAEs were defined as adverse events characterized by a potential association with inflammation and considered by the investigator as drug related.
These prespecified terms were grouped into the following organ-specific subcategories: gastrointestinal, hepatic, skin, endocrine, neurologic, and other (includes blood, eye, immune system, investigations, infections, renal, and respiratory systems).
Patients may have 1 or more events.
|
From first dose of study drug during reinduction to the earliest of 70 days after last dose or day before second reinduction first dose date
|
|
Progression-free Survival (PFS)
기간: From day of first reinduction in current study to date of progression or death, whichever occurred first.
|
PFS was defined as the time between the date of the baseline tumor assessment in this study and the date of progression or death, whichever occurred first.
|
From day of first reinduction in current study to date of progression or death, whichever occurred first.
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2006년 5월 1일
기본 완료 (실제)
2012년 9월 1일
연구 완료 (실제)
2014년 4월 1일
연구 등록 날짜
최초 제출
2005년 9월 9일
QC 기준을 충족하는 최초 제출
2005년 9월 9일
처음 게시됨 (추정)
2005년 9월 13일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2016년 7월 27일
QC 기준을 충족하는 마지막 업데이트 제출
2016년 6월 28일
마지막으로 확인됨
2016년 6월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CA184-025
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .